本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2024/7/221 分钟阅读
Determination of Regulatory Review Period for Purposes of Patent Extension; XENPOZYME; Correction
本地自动翻译 · 来源原始语言
摘要
The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 2, 2024. The document announced the determination of the regulatory review period for XENPOZYME (olipudase alfa-rpcp) for purposes of patent extension. The document was published with an incorrect patent number. This notice corrects the patent number.
来源原始语言: Federal Register — Food and Drug Administration打开原始公告 →